Nuvation Bio Q4 net loss $25.1M, cash $765.4M; NUV-422 gets Fast Track

Nuvation Bio Inc.

2022-FY EPS reported -$0.44

Net loss Q4 2021 was $25.1M ($0.12/share) vs $13.3M ($0.11) in Q4 2020.
Full-year 2021 net loss $86.8M vs $41.7M in 2020; R&D spend $69.0M (up from $32.6M).
Cash, equivalents, and marketable securities $765.4M as of Dec 31, 2021.
FDA Fast Track for NUV-422 (high-grade gliomas); IND cleared for NUV-868 (solid tumors).
Expects Phase 1 safety data for NUV-422 in 2022; multiple pipeline milestones planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.